The measles-mumps-rubella (MMR) vaccine is a live-attenuated combined vaccine employed to combat infectious diseases (measles, rubella and mumps). It is also indicated in distinctive patient populations as post-exposure prophylaxis (PEP) to rubella, mumps, and/or measles.

Indications for the measles-mumps-rubella (MMR) vaccine

• Measles-containing vaccines are suggested for the routine immunisation of children and adolescents who have not been immunised on a regular program.
• It is also indicated for adults born after 1970 (who have not received immunisation).
• Adults born before 1970 can be considered to possess natural immunity to measles; still, military personnel, healthcare workers, and susceptible travellers should receive the MMR vaccine. 
• Women should be vaccinated before or during their reproductive years because rubella can lead to congenital malformations in the foetus.
• Non-immunised female patients willing to become pregnant must be vaccinated with the MMR vaccine in no <1 month before becoming pregnant.
• Pregnant women might be administered the MMR vaccine in measles or rubella outbreaks as the benefits of vaccination outweigh the risks.
• The MMR vaccine must be administered after delivery to non-immunised patients, as it is safe during breastfeeding.
• MMR vaccine can be given as PEP to the following individuals:

• Patients between 6-12 months old who are immunocompetent and have had an exposure in the last 72 hours and non-pregnant women 12 months or older who are immunocompetent with exposure in the previous 6 days.
• Individuals <six months, between 6-12 months, and who have suffered exposure >72 hours ago, pregnant, or immunocompromised must receive an immunoglobin preparation for PEP